# ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study

Source: https://onco.cc/trials/nct05596409/  
OnCo record `nct05596409` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Elacestrant in HR-positive / HER2-negative breast cancer, run by Stemline Therapeutics, Inc., active and no longer recruiting.

## Summary

ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study is a phase 2 interventional study registered as NCT05596409 by Stemline Therapeutics, Inc., with 61 participants enrolled, started 2023-05-19 and due to reach its primary completion in 2026-11. Interventions recorded: Elacestrant.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05596409
- Phase: 2
- Setting: ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer: An Open-Label Multicenter Phase 2 Study (ELCIN)
- Sponsor: Stemline Therapeutics, Inc.
- Enrolled: 61

## Sources

- ClinicalTrials.gov NCT05596409: https://clinicaltrials.gov/study/NCT05596409

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/)
- drugs: [Elacestrant](https://onco.cc/drugs/elacestrant/)
- companies: [Menarini / Stemline](https://onco.cc/companies/menarini/)

---
JSON: https://onco.cc/api/v1/entities/nct05596409.json